Stock Ratings / Health Care / QTTB / earnings

AMRN (43) BCYC (24) ABEO (39) IMRX (45) ⌘ Pro Terminal →

Q32 Bio Inc. (QTTB) Next Earnings Date & Expected ±12.5% Move

$8.87 -2.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Q32 Bio Inc. (QTTB) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $264.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QTTB)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.11 Expected Swing

MODEL EARNINGS SETUP GAUGE

QTTB Quantitative Pre-Earnings Setup: 61/100

Trailing EPS: $1.00 • YoY Revenue Growth: 12.4%

Model Bullish Setup (61/100)Model Risk Weight (39/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$53.7M	$29.8M	-$33.5M	52%
FY 2024	2024-12-31	$0	-$47.7M	-$67.8M	52%
FY 2023	2023-12-31	$1.2M	-$53.7M	-$18.7M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating QTTB & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on QTTB
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

QTTB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +58.39%📐 HORIZONTAL RANGE

2026-10-30O $8.87H $8.98L $8.52C $8.87VOL 268.1K

RES: $19.90SUP: $6.77SMA50: $10.45SMA200: $9.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QTTB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QTTB Butterfly Map → + Track QTTB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-3.4%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QTTB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QTTB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for QTTB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QTTB)

Health Care Rank #194 of 1016 ⚔️ AMRN vs QTTB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QTTB vs. AMRN, BCYC, ABEO, IMRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Q32 Bio Inc. (QTTB) ranks #194 by composite RQD confidence (61/100, grade C-) and #537 by equity capitalization ($264.1M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
QTTB ACTIVE Q32 Bio Inc.	C-	61/100	8.9x	—	85.0%	-2.10%	$264.1M	Benchmark Subject
AMRN Amarin Corporation plc	D-	43/100	—	56.6%	-12.2%	-0.08%	$262.8M	/amrn-vs-qttb →
BCYC Bicycle Therapeutics plc	E	24/100	—	—	-35.0%	-1.55%	$267.4M	/bcyc-vs-qttb →
ABEO Abeona Therapeutics Inc.	D-	39/100	—	73.7%	-35.0%	+0.22%	$260.8M	/abeo-vs-qttb →
IMRX Immuneering Corporation (Class A)	D	45/100	—	—	-35.0%	+0.75%	$260.1M	/imrx-vs-qttb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001661998

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Q32 Bio Inc. (QTTB) reported GAAP revenue of $53.7M (N/A vs. FY2024 revenue of $0 , and +4548.5% cumulative change since FY2023) , GAAP net income of $29.8M, operating cash flow of -$33.5M, and free cash flow of -$33.5M (+50.5% YoY). On the balance sheet, QTTB closed FY2025 with $61.8M in total assets against $0 in total debt (Altman Z-Score: 5.99, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$53.7M	$29.8M	-$33.5M	-$33.5M	$61.8M	—
FY2024 (FY)	2024-12-31	$0	-$47.7M	-$67.7M	-$67.8M	$92.3M	—
FY2023 (FY)	2023-12-31	$1.2M	-$53.7M	-$18.7M	-$18.7M	—	—

3. QTTB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QTTB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Q32 Bio Inc. (NASDAQ: QTTB) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $8.87 (-2.10% 1D, market cap $264.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, QTTB ranks #194 in composite RQD confidence.

How does QTTB compare to AMRN and BCYC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QTTB carries a Roarable C- (61/100 RQD), trailing P/E of 8.9x, gross margin of —, and ROIC of 85.0%. By comparison, AMRN (Amarin Corporation plc) holds a D- grade (43/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M) and BCYC (Bicycle Therapeutics plc) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $267.4M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QTTB?

Per QTTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661998), Q32 Bio Inc. generated $53.7M in revenue, $29.8M in net income, and -$33.5M in free cash flow against $61.8M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QTTB trading relative to its 50-day, 200-day, and 52-week technical levels?

QTTB last traded at $8.87 (-2.10% on volume of 317,945 shares), positioning the stock -15.12% below its 50-day simple moving average ($10.45) and -4.00% below its 200-day simple moving average ($9.24). Across its 52-week range of $1.91 to $23.57, QTTB sits at the 32.1% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.76 to $9.98).